Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Egorin

Showing results (91-100 of 159) with videos related to

Pageof 16
Sort By:
Cancer Research|March 1, 1985
Cellular pharmacology in murine and human leukemic cell lines of diaziquone (NSC 182986)M J Egorin, B M Fox, J F Spiegel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1989
Phase I clinical and pharmacokinetic study of thiotepa administered intraperitoneally in patients with advanced malignanciesS Wadler, M J Egorin, E G Zuhowski, et al.
Cancer Chemotherapy and Pharmacology|August 14, 1999
Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agentM J Egorin, E G Zuhowski, D L Sentz, et al.
Clinical Pharmacology and Therapeutics|July 1, 1982
Cyclophosphamide plasma and cerebrospinal fluid kinetics with and without dimethyl sulfoxideM J Egorin, R S Kaplan, M Salcman, et al.
Journal of the National Cancer Institute|March 16, 1988
Phase I and pharmacokinetic trial of carboplatin in refractory adult leukemiaE J Lee, M J Egorin, D A Van Echo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1989
A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposideC P Belani, M J Egorin, J S Abrams, et al.
Cancer Research|November 15, 1987
Plasma pharmacokinetics and urinary excretion of hexamethylene bisacetamide metabolitesM J Egorin, E G Zuhowski, A S Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancerJ A Sparano, J Speyer, W J Gradishar, et al.
Seminars in Oncology|December 1, 1996
Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and responseM J Glantz, H Choy, W Akerley, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicinB A Conley, M J Egorin, M Y Whitacre, et al.
Pageof 16

Showing results (91-100 of 159) with videos related to

Sort By:
Pageof 16
Cancer Research|March 1, 1985
Cellular pharmacology in murine and human leukemic cell lines of diaziquone (NSC 182986)M J Egorin, B M Fox, J F Spiegel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1989
Phase I clinical and pharmacokinetic study of thiotepa administered intraperitoneally in patients with advanced malignanciesS Wadler, M J Egorin, E G Zuhowski, et al.
Cancer Chemotherapy and Pharmacology|August 14, 1999
Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agentM J Egorin, E G Zuhowski, D L Sentz, et al.
Clinical Pharmacology and Therapeutics|July 1, 1982
Cyclophosphamide plasma and cerebrospinal fluid kinetics with and without dimethyl sulfoxideM J Egorin, R S Kaplan, M Salcman, et al.
Journal of the National Cancer Institute|March 16, 1988
Phase I and pharmacokinetic trial of carboplatin in refractory adult leukemiaE J Lee, M J Egorin, D A Van Echo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1989
A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposideC P Belani, M J Egorin, J S Abrams, et al.
Cancer Research|November 15, 1987
Plasma pharmacokinetics and urinary excretion of hexamethylene bisacetamide metabolitesM J Egorin, E G Zuhowski, A S Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancerJ A Sparano, J Speyer, W J Gradishar, et al.
Seminars in Oncology|December 1, 1996
Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and responseM J Glantz, H Choy, W Akerley, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicinB A Conley, M J Egorin, M Y Whitacre, et al.
Pageof 16